A Study to Create a Research Database by Gathering Information about Peyronie’s Disease and the Effects it has on Erectile Dysfunction

Overview

About this study

The purpose of this investigation is to develop and maintain a database for patients with PD +/- ED in the five years preceding the introduction of collagenase histolyticum (2008-2013) in comparison to the five years following Xiaflex FDA approval (2013-2018).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:    

Mayo Clinic Jacksonville patients seen in the Urology Department who underwent CDDU analysis for PD performed by a single surgeon (Dr. Gregory Broderick, PI) within the specified timeline.

Patients will include those that have received treatment of Xiaflex for PD since FDA approval.

Exclusion Criteria:  

Excluded patients are those who have not received treatment of Xiaflex for PD by Dr. Gregory Broderick at Mayo Clinic Jacksonville within the specified timeframe.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Gregory Broderick, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20492878

Mayo Clinic Footer